There are multiple factors that may have influenced heterogeneity including differences in the target populations, variations in dosing or discontinuation rates, degree of inflammation as measured by C-reactive protein, the presence of newer inflammatory diseases such as COVID-19, and the effect of an unexpected pandemic on the reporting of cardiovascular events. The gene discussed is CRP; the disease is COVID-19.